Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Leucovorin 4venetoclax 3Specimen Handling 3Fluorouracil 3Doxorubicin 3Cytarabine 3Cyclophosphamide 3Bevacizumab 3trametinib 2pembrolizumab 2dabrafenib 2Taxes 2Sorafenib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-2 2Gemcitabine 2Daunorubicin 2Carboplatin 2Bortezomib 2Biopsy 2Azacitidine 2Albumin-Bound Paclitaxel 2vactosertib 1temsirolimus 1ruxolitinib 1romidepsin 1regorafenib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × GSK2141795 × Other hematologic neoplasm × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡